News

Dynacure Receives Orphan Drug Designation…

Strasbourg (France)August 8, 2019

Company expects to initiate Phase 1 / 2 study ‘Unite-CNM’ in 2H2019 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2

READ MORE

Dynacure Receives Orphan Drug Designation…

STRASBOURGJuly 11, 2019

Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation to DYN101 for the treatment of Centronuclear Myopathies (CNM). DYN101, an antisense medicine, is entering a Phase a 1 / 2 study (Unit

READ MORE

Dynacure Announces Approval of Clinical…

Strasbourg (France)April 30, 2019

Company expects to initiate Phase 1 / 2 study ‘Unite-CNM’ in 2H2019 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Clinical Trial Application (CTA) for DYN101, an investigational antisense medicine designed to modu

READ MORE

Dynacure receives Research Grant from…

Strasbourg (France)April 25, 2019

Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the award of a research grant of 450 000 euros from Programme d’Investissements d’Avenir (PIA3) Grand Est operated by Bpifrance. The research grant will advance and expand the development of Dynacure’s lead drug program (Dyn-101), an antisense oligonucleotide des

READ MORE

Dynacure promotes Belinda Cowling (PhD)…

StrasbourgFebruary 12, 2019

Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the promotion of Belinda Cowling (PhD) to Chief Scientific Officer and Leen Thielemans (PhD) to Chief Development Officer. Belinda Cowling’s (PhD) research at the IGBMC (Strasbourg) led to the creation of Dynacure in 2016, of which she is cofounder and was scientific

READ MORE

Dynacure appoints Georges Gemayel (PhD)…

StrasbourgOctober 9, 2018

Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the appointment of Georges Gemayel (PhD) as chairman of its Board of Directors. "I am very pleased to welcome Georges to Dynacure’s Board of Directors during this exciting stage in our company's growth. His extensive experience will strengthen the team’s mission to

READ MORE

Innovative modelling approach by Dynacure/ISMS…

StrasbourgAugust 31, 2018

Dynacure’s recent publication in ‘Neuromuscular Disorders’, co-authored with Dr Laurent Servais, Dr Jim Dowling and Dr Valérie Biancalana: ‘An integrated modelling methodology for estimating the prevalence of centronuclear myopathy’  This innovative modelling approach by Dynacure/ISMS resulted in the 1st peer reviewed study on quantification of the CNM patient population with a d

READ MORE

Dynacure names Chris Freitag (MD)…

Strasbourge (France)July 10, 2018

Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the expansion of its leadership team with the appointment of Chris Freitag (MD) as Chief Medical Officer. He will be responsible for the company’s medical strategy, clinical operations and expand Dynacure’s network with medical and academic organizations. “I’m e

READ MORE

Dynacure secures €47 million financing…

Strasbourge (France)July 6, 2018

Financing will support clinical development of lead antisense oligonucleotide candidate for centronuclear myopathy (CNM), and additional preclinical research programs forotherorphan disorders Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the completion of a €47 million financing round (~US$55 million) to advance

READ MORE

Belinda Cowling (PhD) joins Dynacure…

Strasbourg (France)April 30, 2018

Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today that Belinda Cowling (PhD) has joined the management team as Head of Research.  Dynacure’s first drug discovery program focuses on centronuclear myopathies (CNM), a rare debilitating disease affecting children and young adults, through the use of an antisense oligonu

READ MORE

Ionis licenses novel antisense drug…

Carlsbad, Calif. and Strasbourg, FranceNovember 9, 2017

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure equity. Dynacure will now assume all development and commercialization responsibilities for the pro

READ MORE

Dynacure joins ongoing Natural History…

Strasbourg (France)September 26, 2017

Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathy (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. Dynac

READ MORE

Dynacure appoints its Management Team…

Strasbourg (France)March 9, 2017

Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. The

READ MORE

Kurma Partners and Idinvest Partners…

ParisOctober 24, 2016

Kurma announced on Monday the 24th of October 2016, that they have entered into a collaboration agreement with Conectus and Ionis Pharmaceutical to launch Dynacure, a Strasbourg-based biotech specializing in the treatment of rare neuromuscular disorders. Dynacure is a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg. “The

READ MORE